Adagene Inc. announced on July 15, 2025, that it is seeking regulatory approval from the FDA for its therapy, which involves collaboration with Merck.
1 report, 1 independent
Updated Jul 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Adagene Inc. announced on July 15, 2025, that it is seeking regulatory approval from the FDA for its therapy, which involves collaboration with Merck.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.
- Merck has set the list price for a drug that received approval from the FDA.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- Experimental therapies require approval from the FDA.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
Coverage
Newest first; wire copies grouped- GlobeNewswireAdagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - Alignment ga